πŸ‡ΊπŸ‡Έ FDA
Patent

US 11820773

Tricyclic compounds

granted A61KA61K31/519A61K31/675

Quick answer

US patent 11820773 (Tricyclic compounds) held by Aligos Therapeutics, Inc. expires Mon Nov 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Aligos Therapeutics, Inc.
Grant date
Tue Nov 21 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
21
CPC classes
A61K, A61K31/519, A61K31/675, A61K45/06, A61P